Table 2 The association between TS polymorphism and clinical outcomes

Goekkurt 2006 [11]

3R3R: 3/12; 2R2R+2R3R: 9/32

NR

NR

Ruzzo 2006 [14]

3R3R: 22/61; 2R2R+2R3R: 48/114

NR

NR

Han 2010 [19]

3R3R: 16/28; 2R2R+2R3R: 5/10

NR

NR

Seo 2009 [21]

NR

NR

NSS

Shitara 2010 [27]

NR

(2R2R+2R3R)/3R3R: 1.28 (0.85, 1.96)

NSS

Huang 2009 [28]

NR

(2R2R+2R3R)/3R3R: 1.54 (0.879, 2.698)

NR

Ishida 2002 [29]

NR

(2R2R+2R3R)/3R3R: 1.26 (0.81, 1.95)

NR

Goekkurt 2009 [31]

3R3R: 17/33; 2R2R+2R3R: 35/101

NR

Grade 3/4 leukopenia: P=0.047

Ott 2006 [32]

3R3R: 10/41; 2R2R+2R3R: 23/94

2R2R/3R3R: 0.33 (0.22, 0.51); 2R3R/3R3R: 0.52 (0.37, 0.74)

NR

Lee 2005 [34]

NR

(2R2R+2R3R)/3R3R: 1.16 (0.68, 1.99)

NR

Combined analysis(OR/HR, 95CI %)

OR: (2R2R+2R3R)/3R3R

(2R2R+2R3R)/3R3R

___

Total: 0.92 (0.62, 1.37);

Total: 1.29 (1.02, 1.64)

RECIST subgroup: 0.93 (0.33, 2.63);

All studies reported the data were Asian

Others subgroup: 0.92 (0.60, 1.41);

Palliative subgroup: 1.16 (0.68, 1.98)

Asian subgroup: 0.75 (0.18, 3.19);

Adjuvant subgroup: 1.33 (1.02, 1.73)

European subgroup: 0.94 (0.62, 1.41)

Palliative subgroup: 0.90 (0.58, 1.40)

Neoadjuvant subgroup: 1.00 (0.43, 2.36)